Table 4 Crude and adjusted Hazards Ratios for Carcinosarcoma Overall survival (OS) estimated by univariate analysis and multivariate analysis

Age

1.02

0.98–1.07

0.307

1.03

0.98–1.08

0.157

Stage (I/II vs III/IV)

0.28

0.11–0.71

0.008

–

Residual disease (R1/2 vs R0)

3.83

1.92–7.62

0.001

2.87

1.40–5.89

0.003

Adjuvant radiotherapy (Yes vs No)

0.53

0.27–1.05

0.068

0.64

0.32–1.28

0.214

LVI (present vs absent)

1.05

0.47–2.35

0.900

0.99

0.44–2.22

0.985

Histological subtype (Homologous vs Heterologous)

0.84

0.38–1.87

0.671

0.90

0.40–2.01

0.806

CD3_E (high vs low)

0.52

0.27–0.99

0.047

0.65

0.33–1.25

0.200

CD3_S (high vs low)

0.54

0.16–1.79

0.315

0.73

0.22–2.42

0.605

CD4_E (high vs low)

0.52

0.26–1.01

0.054

0.56

0.28–1.11

0.972

CD4_S (high vs low)

0.66

0.32–1.33

0.241

0.60

0.30–1.22

0.160

CD8_E (high vs low)

0.69

0.35–1.39

0.301

0.60

0.29–1.23

0.163

CD8_S (high vs low)

0.77

0.37–1.59

0.478

0.61

0.29–1.28

0.193

FOXP3_E (high vs low)

0.46

0.20–1.06

0.069

0.43

0.18–1.01

0.052

FOXP3_S (high vs low)

0.24

0.06–0.99

0.048

0.26

0.06–1.09

0.066

PD-1_E (high vs low)

0.33

0.16–0.68

0.002

PD-1_S (high vs low)

0.46

0.19–1.10

0.080

0.52

0.22–1.27

0.152

PD-L1_E (high vs low)

0.54

0.28–1.03

0.062

0.49

0.25–0.96

0.037

PD-L1_S (high vs low)

0.34

0.14–0.81

0.015

0.37

0.15–0.90

0.028

PD-L2_E (high vs low)

0.56

0.24–1.29

0.173

0.76

0.32–1.77

0.519

PD-L2_S (high vs low)

0.44

0.13–1.44

0.174

0.41

0.12–1.35

0.144

CD4/FOXP3_E ratio (high vs low)

0.67

0.36–1.27

0.223

0.76

0.40–1.45

0.407

CD4/FOXP3_S ratio (high vs low)

1.83

0.92–3.65

0.086

2.04

1.02–4.09

0.043

CD8/FOXP3_E ratio (high vs low)

0.68

0.35–1.33

0.262

0.79

0.40–1.57

0.506

CD8/FOXP3_S ratio (high vs low)

2.22

1.14–4.29

0.018

1.91

0.98–3.73

0.058

CD8/CD4_E ratio (high vs low)

0.69

0.27–1.78

0.446

0.58

0.23–1.51

0.268

CD8/CD4_S ratio (high vs low)

0.98

0.39–2.53

0.969

1.16

0.45–3.01

0.754